Skip to content

Study Designed to Clinically Evaluate Sinus Wash Device Prototypes

Pilot Study Designed to Clinically Evaluate Sinus Wash Device Prototypes in Patients With Sinusitis During Endoscopic Sinus Surgery (ESS) and in the Hospital Outpatient

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02931604
Enrollment
50
Registered
2016-10-13
Start date
2017-01-31
Completion date
2020-01-31
Last updated
2016-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Maxillary Sinusitis, Sinusitis

Keywords

sinus wash, sinus lavage, Sinusitis

Brief summary

The purpose of this study is to clinically evaluate sinus wash device prototypes in patients with sinusitis during Endoscopic Sinus Surgery (ESS) and in the hospital outpatient

Interventions

DEVICESinuSafe Medical Device for Maxillary Sinus

Sinus lavage via the natural sinus ostium, without ostial dilation.

Sponsors

SinuSafe Medical LTD
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Male or female, 18-65 years of age. 2. Signs and symptoms of acute exacerbation during chronic maxillary sinusitis. 3. Pain higher than 5 in VAS of 0-10. 4. Able to understand and provide written informed consent.

Exclusion criteria

1. Patients who have a clinically significant or unstable medical or surgical condition that may preclude safe and complete study participation as determined by medical history based on the opinion of the investigator. 2. Extensive sinonasal polyps that may interfere with the treatment procedure. 3. Previous sinonasal surgery. 4. Acute exacerbation of sinusitis in the frontal or sphenoid sinuses. 5. Sinonasal osteoneogenesis. 6. Cystic fibrosis. 7. Sinonasal tumors or obstructive lesions. 8. Presence of features consistent with sinus fungal disease on CT or physical examination. 9. History of facial trauma that distorted the sinus anatomy. 10. Ciliary dysfunction. 11. History of insulin dependent diabetes. 12. Not able to stop anti-coagulant (e.g., warfarin) until the International Normalized Ratio (INR) is below 1.5. 13. Not able to stop anti-platelet (e.g., clopidogrel, aspirin, etc.) for at least 14 days prior to study procedure. 14. Not able to stop any non-steroidal anti-inflammatory medications and homeopathic medications for at least 14 days prior to the study procedure. 15. Pregnancy. 16. Psychiatric disease. 17. Currently participating in other drug or device studies. 18. Investigator's opinion that the subject should not be in the study such as any conditions that could compromise the wellbeing of the patient or integrity of the study or prevent the patient from meeting or performing study requirements. 19. Patient is not capable of following the study schedule for any reason.

Design outcomes

Primary

MeasureTime frameDescription
Adverse eventsWithin day 1Presence of adverse events

Secondary

MeasureTime frameDescription
Syringe visual inspectionWithin 1 hourVisual inspection of the aspirated liquids looking for bleeding. Excess nasal bleeding shall be defined as a doctor decision to use sinus or nasal packing.
Pain during procedureWithin 1 hourPain during procedure with the VAS pain scale
Usability & Tolerability QuestionnaireWithin 1 hourUsability & Tolerability Questionnaire
Mucus leftovers visual inspectionWithin 1 hourVisual inspection of sinus mucosa with the endoscope looking for mucus leftovers
Mucosal damage visual inspectionWithin 1 hourVisual inspection of sinus mucosa with the endoscope looking for mucosal damage.
Pain reliefWithin 1 hourPain relief in the post-treatment VAS pain scale
Time measurements of cannula insertion.Within 1 hourTime measurements of cannula insertion
Time measurements of irrigation and aspirationWithin 1 hourTime measurements of irrigation and aspiration
SNOT 20 questionnaireWithin 1 hourSNOT 20 questionnaire (Hebrew version) to evaluate the patient's severity level before the treatment
Mucus aspiration into the syringeWithin 1 hourMucus aspiration into the syringe (yes/ no and time)

Contacts

Primary ContactAvinoam Gemer
avinoamgemer@gmail.com972-544-858822

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026